Quick Answer: Yes — clinical research demonstrates significant visceral adipose tissue reduction in study populations. It is FDA-approved specifically for HIV-associated lipodystrophy and operates by stimulating endogenous growth hormone secretion through GHRH receptor agonism.
Among the peptides that have attracted sustained scientific interest for their effects on body composition, few carry the combination of regulatory pedigree and mechanistic specificity that characterises tesamorelin. Unlike many compounds discussed in research and wellness circles that remain purely investigational, tesamorelin holds a genuine FDA approval — a fact that grounds any discussion of its fat-reducing properties in a framework of peer-reviewed clinical evidence rather than hypothesis alone. The question of whether it can burn fat is not merely speculative; it has been systematically studied in randomised controlled trials, and the data are both robust and reproducible.
🔗 Related Reading: For a comprehensive overview of Tesamorelin research, mechanisms, UK sourcing, and safety data, see our Tesamorelin UK: Complete Research Guide (2026).
